Mithramycin

Ewing Sarcoma

National Cancer Institute (NCI)Phase 1/2Dormant

D

26/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 11/ 100
Competitive Position: 81/ 100

Competitive context

57 Active assets in the Ewing Sarcoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Milton S. Hershey Medical Center	Phase 3	BB
Nivolumab Children's National Research Institute	Phase 2	B
Cyclophosphamide Essen Biotech	Phase 2	B
Hycamtin Pfizer	Phase 2	B
Inno-206 Children's National Research Institute	Phase 2	B

View all 50 →

Same molecule, other indications

Mithramycin is also rated in:

esophageal cancerDormant

D

Indicative ·

30 / 100

mesotheliomaDormant

D

Indicative ·

30 / 100

lung cancerDormant

D

Indicative ·

29 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.